

Carbon Reduction Plan

Supplier name: Gilead Sciences, Inc.

Publication date: 08 August 2024

Commitment to achieving Net Zero

Gilead Sciences, Inc. is committed to achieving Net Zero Operations emissions by 2030.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions.

Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year: 2019

Additional Details relating to the Baseline Emissions calculations.

As part of Gilead's continued commitment to transparency in our progress against our environmental goals, we report our environmental performance data for 2019-2023 on Gilead.com.

Our greenhouse gas (GHG) emissions and energy consumption data have been third-party verified by APEX Companies LLC using the ISO 14064-3: Greenhouse Gases - Part 3 specification standard. Additionally, we verify our global water withdrawal, hazardous, and non-hazardous waste production volumes through APEX using the International Standard on Assurance Engagements (ISAE) 3000 Revised.

APEX conducted an independent, limited assurance verification of our reported data, assessing its accuracy and the underlying systems and processes used to collect, analyze, and review the information.

All reported values represent the best available data at the time of publication. The GHG emissions values are reported in CO₂e (carbon dioxide equivalent) for the seven greenhouse gases covered by the Kyoto Protocol (Carbon dioxide (CO₂), Methane (CH₄), Nitrous oxide (N₂O), Hydrofluorocarbons (HFCs), Perfluorocarbons (PFCs), Sulphur hexafluoride (SF₆) and Nitrogen trifluoride (NF₃)).

Some environmental data from previous years have been restated due to acquisitions, changes in methodology and/or accuracy improvements. All reporting year data goes through third-party limited assurance.

Baseline year emissions:

EMISSIONS	TOTAL (tCO ₂ e)																																
Scope 1	54,098																																
Scope 2	33,331																																
Scope 3 (Included Sources)	1,092,883																																
	<table border="1"> <thead> <tr> <th>Scope 3 Category</th> <th>MTCO₂e</th> </tr> </thead> <tbody> <tr> <td>Purchased Goods & Services ^{2,5}</td> <td>608,432</td> </tr> <tr> <td>Capital Goods ^{2,5}</td> <td>98,941</td> </tr> <tr> <td>FERA ^{1,3}</td> <td>14,821</td> </tr> <tr> <td>Upstream Transport & Distribution ^{1,2,3,5}</td> <td>53,051</td> </tr> <tr> <td>Waste ^{1,3}</td> <td>5,166</td> </tr> <tr> <td>Business Travel (required only) ^{1,2,3,5}</td> <td>50,290</td> </tr> <tr> <td>Employee Commuting ^{1,2}</td> <td>23,656</td> </tr> <tr> <td>Upstream Leased Assets ⁴</td> <td>N/A</td> </tr> <tr> <td>Downstream Transport & Distribution ¹</td> <td>192</td> </tr> <tr> <td>Processing of Sold Products ⁴</td> <td>N/A</td> </tr> <tr> <td>Use of Sold Products ⁴</td> <td>N/A</td> </tr> <tr> <td>End of Life Treatment of Sold Products ^{1,6}</td> <td>7</td> </tr> <tr> <td>Downstream Leased Assets ⁴</td> <td>N/A</td> </tr> <tr> <td>Franchises ⁴</td> <td>N/A</td> </tr> <tr> <td>Investments ^{1,2}</td> <td>238,326</td> </tr> </tbody> </table>	Scope 3 Category	MTCO ₂ e	Purchased Goods & Services ^{2,5}	608,432	Capital Goods ^{2,5}	98,941	FERA ^{1,3}	14,821	Upstream Transport & Distribution ^{1,2,3,5}	53,051	Waste ^{1,3}	5,166	Business Travel (required only) ^{1,2,3,5}	50,290	Employee Commuting ^{1,2}	23,656	Upstream Leased Assets ⁴	N/A	Downstream Transport & Distribution ¹	192	Processing of Sold Products ⁴	N/A	Use of Sold Products ⁴	N/A	End of Life Treatment of Sold Products ^{1,6}	7	Downstream Leased Assets ⁴	N/A	Franchises ⁴	N/A	Investments ^{1,2}	238,326
Scope 3 Category	MTCO ₂ e																																
Purchased Goods & Services ^{2,5}	608,432																																
Capital Goods ^{2,5}	98,941																																
FERA ^{1,3}	14,821																																
Upstream Transport & Distribution ^{1,2,3,5}	53,051																																
Waste ^{1,3}	5,166																																
Business Travel (required only) ^{1,2,3,5}	50,290																																
Employee Commuting ^{1,2}	23,656																																
Upstream Leased Assets ⁴	N/A																																
Downstream Transport & Distribution ¹	192																																
Processing of Sold Products ⁴	N/A																																
Use of Sold Products ⁴	N/A																																
End of Life Treatment of Sold Products ^{1,6}	7																																
Downstream Leased Assets ⁴	N/A																																
Franchises ⁴	N/A																																
Investments ^{1,2}	238,326																																
	<p>Scope 3 GHG Emissions Footnotes</p> <p>1. Scope 3 emissions based on primary data</p> <p>2. Scope 3 emissions based on spend data (EEIO or supplier allocations)</p> <p>3. Scope 3 verified emissions (FERA, waste, business air travel in all years; upstream transportation and distribution from 2022 onward)</p>																																

	<p>4. N/A: These categories are not applicable to Gilead. Upstream leased assets: all leased assets are reported in Gilead's Scope 1 and 2 emissions. Processing of sold products: Gilead products are not subject to further processing after they are sold. Use of sold products: The use of Gilead's therapeutic products does not cause GHG emissions. Downstream leased assets: Gilead does not sublet sites. Franchises: Gilead does not have franchises. 5. Updated EEIO emissions methodology is reflected in 2019/2022/2023. 2020 and 2021 EEIO emissions may be updated in future. 6. Due to the immateriality of these emissions, the End of Life Treatment of Sold Products emissions have been held flat year-over-year.</p>
Total Emissions	1,180,312

Current Emissions Reporting

Reporting Year: 2023		
EMISSIONS	TOTAL (tCO₂e)	
Scope 1	56,096	
Scope 2	22,339	
Scope 3 (Included Sources)	1,121,798	
	Scope 3 Category	MTCO₂e
	Purchased Goods & Services ^{2,5}	828,191
	Capital Goods ^{2,5}	67,687
	FERA ^{1,3}	15,219
	Upstream Transport & Distribution ^{1,2,3,5}	68,315
	Waste ^{1,3}	3,300
	Business Travel (required only) ^{1,2,3,5}	56,569
	Employee Commuting ^{1,2}	39,143
	Upstream Leased Assets ⁴	N/A

	<table border="1"> <tbody> <tr> <td>Downstream Transport & Distribution ¹</td> <td>126</td> </tr> <tr> <td>Processing of Sold Products ⁴</td> <td>N/A</td> </tr> <tr> <td>Use of Sold Products ⁴</td> <td>N/A</td> </tr> <tr> <td>End of Life Treatment of Sold Products ^{1,6}</td> <td>7</td> </tr> <tr> <td>Downstream Leased Assets ⁴</td> <td>N/A</td> </tr> <tr> <td>Franchises ⁴</td> <td>N/A</td> </tr> <tr> <td>Investments ^{1,2}</td> <td>43,241</td> </tr> </tbody> </table> <p>Scope 3 GHG Emissions Footnotes</p> <p>1. Scope 3 emissions based on primary data</p> <p>2. Scope 3 emissions based on spend data (EEIO or supplier allocations)</p> <p>3. Scope 3 verified emissions (FERA, waste, business air travel in all years; upstream transportation and distribution from 2022 onward)</p> <p>4. N/A: These categories are not applicable to Gilead. Upstream leased assets: all leased assets are reported in Gilead's Scope 1 and 2 emissions. Processing of sold products: Gilead products are not subject to further processing after they are sold. Use of sold products: The use of Gilead's therapeutic products does not cause GHG emissions. Downstream leased assets: Gilead does not sublet sites. Franchises: Gilead does not have franchises.</p> <p>5. Updated EEIO emissions methodology is reflected in 2019/2022/2023. 2020 and 2021 EEIO emissions may be updated in future.</p> <p>6. Due to the immateriality of these emissions, the End of Life Treatment of Sold Products emissions have been held flat year-over-year.</p>	Downstream Transport & Distribution ¹	126	Processing of Sold Products ⁴	N/A	Use of Sold Products ⁴	N/A	End of Life Treatment of Sold Products ^{1,6}	7	Downstream Leased Assets ⁴	N/A	Franchises ⁴	N/A	Investments ^{1,2}	43,241
Downstream Transport & Distribution ¹	126														
Processing of Sold Products ⁴	N/A														
Use of Sold Products ⁴	N/A														
End of Life Treatment of Sold Products ^{1,6}	7														
Downstream Leased Assets ⁴	N/A														
Franchises ⁴	N/A														
Investments ^{1,2}	43,241														
Scope 3 (Included Sources)	1,121,798														
Total Emissions	1,200,233														

Emissions reduction targets

In order to continue our progress to achieving Net Zero operations, we have adopted the following carbon reduction targets. Our carbon reduction target has been approved by [Science Based target Initiative \(SBTi\)](#) and is in line with the 1.5 degree Celsius pathway. Gilead is a signatory of The Climate Group's [RE100](#) and [EV100](#) initiatives to help accelerate progress towards 100% renewable electricity and help drive the transition to electric vehicles, respectively.

- Reduce Scope 1 and 2 GHG emissions by 46% by 2030 (SBTi target)
- Transition 100% of fleet vehicles to electric or low emissions vehicles and increase charging infrastructure by 2030 (EV100)
- Utilize 100% renewable electricity in operations by 2025 (RE100)
- Achieve carbon net-zero operation GHG emissions by 2030

In addition, we have a Scope 3 reduction target approved by SBTi, and is in line with the 2 degree Celsius pathway and will reduce our Scope 3 GHG emissions by 15% by 2030. We are committed to revisiting and strengthening our commitments on a periodic basis.

We project that our Scope 1 and 2 carbon emissions will decrease to 9742 tCO₂e by 2030. This is a reduction of 90%.

Progress against these targets can be accessed in our [annual ESG report](#) and the most up-to-date [performance data](#) may be accessed on the Gilead website.

Carbon Reduction Projects

Completed Carbon Reduction Initiatives

As of 2023, the following environmental management measures and projects have been completed or implemented since the 2019 baseline. The carbon emission reduction achieved by these schemes equate to 8994 tCO₂e, a 10% reduction against the 2019 baseline and the measures will be in effect when performing the contract

Gilead has established a roadmap of initiatives to deliver on our carbon reduction goals. As of 2023:

- 10% reduction of Scope 1 and 2 GHG emissions achieved from 2019 baseline
- 64% of our global electricity is derived from renewable sources; in the UK 3 of 4 facilities are already sourcing 100% renewable electricity
- 8% of our fleet are electric (EV) or plug-in hybrid electric vehicles (PHEV); in the UK we have reduced the emissions associated with our vehicle fleet by 78% since 2019
- 23.7M kWh of energy consumption avoided through implementation of energy efficiency measures
- 25 green building certifications achieved
- 5 solar installations at our facilities in Ireland and the US
- ISO 50001 Certification at our Ireland Manufacturing Facility

In the future we hope to implement further measures such as:

- Source 100% renewable electricity for our operations by 2025
- Continue implementation of energy efficiency projects
- Develop strategies to reduce GHG emissions associated with employee commuting
- Continue to increase the number of electric and low emissions fleet vehicles
- Engage and partner with suppliers to reduce GHG emissions

Declaration and Sign Off


This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard¹ and uses the appropriate Government emission conversion factors for greenhouse gas company reporting².

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard³.

This Carbon Reduction Plan will be implemented by the Gilead Sciences Ltd (GSL) parent company, Gilead Sciences, Inc and has been approved by the board of directors of GSL and signed and dated by a director of GSL

Signed on behalf of Gilead Sciences Ltd:

DocuSigned by:

.....42B7D199005245D.....

August 8, 2024 | 7:14:51 AM PDT
Date:

Document number - UK-AMB-1394

¹<https://ghgprotocol.org/corporate-standard>

²<https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

³<https://ghgprotocol.org/standards/scope-3-standard>